The Series A round was supported by THVP, JIC, MPower, Red Capital, 77 Capital, and Joyo Capital. The addition of DBJ Capital further strengthens our investor base.
The funds will support the development of XF8302, particularly the advancement of a clinical trial targeting dry mouth associated with Sjögren’s disease.
We are grateful for the support of our investors and will accelerate our research and development efforts to bring a new treatment to patients who have long awaited better options.